BACKGROUND: The aim of the study was to compare the effects of 2 strategies of antiplatelet treatment (i.e., 150 mg ASA vs. 75 mg clpoidogrel) on plasma level of inflammatory markers in type 2 diabetes mellitus (T2DM) patients with high platelet reactivity (HPR). METHODS: Study cohort consisted of 304 T2DM patients on chronic ASA therapy (75 mg per day) participating in theAspirin Versus/Or Clopidogrel in Aspirin-resistant Diabetics inflammation Outcomes (AVOCADO) study. Patients with HPR defined as Platelet Function Analyzer (PFA)-100 collagene/epinephrine closure time (CEPI-CT) <; 193 s (n = 80) were randomized to 150 mg of ASA or 75 mg of clopidogrel in 2:3 ratio, respectively. Concentrations of the selected inflammatory markers, including tumor necrosis factor (TNF)-α, interleukin (IL)-6, solubleCD40 ligand (sCD40L), and high sensitivity C-reactive protein (hsCRP), were measured and compared in both treatment groups before and after 8 weeks of treatment in both groups. RESULTS: Out of 234 patients included into final analysis, the total of 34.2% (n = 80) patients displayed HPR, of which 14.1% (n = 33) were randomized into 150 mg of ASA group and 20.1% (n = 47) into 75 mg of clopidogrel group. Treatment with clopidogrel was a positive predictor (stepwise multiple regression analysis) of reduction of sCD40L concentration (odds ratio [OR] 4.15; p = 0.013), while treatment with 150 mg ASA was a positive predictor of reduction of IL-6 concentration (OR 4.38; p = 0.033). There was no statistically significant differences between clopidogrel and ASA 150 mg treatment in respect to predictive value for decreased hsCRP concentrations or increased TNF-α concentrations. CONCLUSIONS: Increasing the dose of ASA from 75 mg to 150 mg daily or switching ASA 75 mg to clopidogrel 75 mg daily may reduce concentrations of some inflammatory markers (in particular hsCRP, IL-6 and CD40L) in T2DM patients with HPR treated previously with 75 mg of ASA.
RCT Entities:
BACKGROUND: The aim of the study was to compare the effects of 2 strategies of antiplatelet treatment (i.e., 150 mg ASA vs. 75 mg clpoidogrel) on plasma level of inflammatory markers in type 2 diabetes mellitus (T2DM) patients with high platelet reactivity (HPR). METHODS: Study cohort consisted of 304 T2DM patients on chronic ASA therapy (75 mg per day) participating in the Aspirin Versus/Or Clopidogrel in Aspirin-resistant Diabetics inflammation Outcomes (AVOCADO) study. Patients with HPR defined as Platelet Function Analyzer (PFA)-100 collagene/epinephrine closure time (CEPI-CT) < 193 s (n = 80) were randomized to 150 mg of ASA or 75 mg of clopidogrel in 2:3 ratio, respectively. Concentrations of the selected inflammatory markers, including tumor necrosis factor (TNF)-α, interleukin (IL)-6, solubleCD40 ligand (sCD40L), and high sensitivity C-reactive protein (hsCRP), were measured and compared in both treatment groups before and after 8 weeks of treatment in both groups. RESULTS: Out of 234 patients included into final analysis, the total of 34.2% (n = 80) patients displayed HPR, of which 14.1% (n = 33) were randomized into 150 mg of ASA group and 20.1% (n = 47) into 75 mg of clopidogrel group. Treatment with clopidogrel was a positive predictor (stepwise multiple regression analysis) of reduction of sCD40L concentration (odds ratio [OR] 4.15; p = 0.013), while treatment with 150 mg ASA was a positive predictor of reduction of IL-6 concentration (OR 4.38; p = 0.033). There was no statistically significant differences between clopidogrel and ASA 150 mg treatment in respect to predictive value for decreased hsCRP concentrations or increased TNF-α concentrations. CONCLUSIONS: Increasing the dose of ASA from 75 mg to 150 mg daily or switching ASA 75 mg to clopidogrel 75 mg daily may reduce concentrations of some inflammatory markers (in particular hsCRP, IL-6 and CD40L) in T2DM patients with HPR treated previously with 75 mg of ASA.
Authors: Marek Postula; Piotr K Janicki; Marek Rosiak; Agnieszka Kaplon-Cieslicka; Agnieszka Kondracka; Ewa Trzepla; Krzysztof J Filipiak; Dariusz A Kosior; Andrzej Czlonkowski; Grzegorz Opolski Journal: Arch Med Sci Date: 2013-05-28 Impact factor: 3.318
Authors: Lukasz Milanowski; Justyna Pordzik; Piotr K Janicki; Agnieszka Kaplon-Cieslicka; Marek Rosiak; Michal Peller; Agata Tyminska; Krzysztof Ozieranski; Krzysztof J Filipiak; Grzegorz Opolski; Dagmara Mirowska-Guzel; Marek Postula Journal: Acta Diabetol Date: 2016-12-19 Impact factor: 4.280
Authors: Ceren Eyileten; Małgorzata Zaremba; Piotr K Janicki; Marek Rosiak; Agnieszka Cudna; Agnieszka Kapłon-Cieślicka; Grzegorz Opolski; Krzysztof J Filipiak; Dariusz A Kosior; Dagmara Mirowska-Guzel; Marek Postula Journal: Med Sci Monit Date: 2016-01-07
Authors: Shuhua Li; Jae Lim Choi; Long Zhe Guo; Ri Young Goh; Bo Ram Kim; Kwang Sook Woo; Moo Hyun Kim; Jin Yeong Han Journal: Ann Lab Med Date: 2016-01 Impact factor: 3.464
Authors: Justyna Pordzik; Ceren Eyileten-Postuła; Daniel Jakubik; Pamela Czajka; Anna Nowak; Salvatore De Rosa; Aleksandra Gąsecka; Agnieszka Cieślicka-Kapłon; Piotr Sulikowski; Krzysztof J Filipiak; Dagmara Mirowska-Guzel; Jolanta M Siller-Matula; Marek Postuła Journal: J Clin Med Date: 2021-05-28 Impact factor: 4.241